NO995843D0 - Farmasöytisk preparat omfattende vWF-propeptid - Google Patents

Farmasöytisk preparat omfattende vWF-propeptid

Info

Publication number
NO995843D0
NO995843D0 NO995843A NO995843A NO995843D0 NO 995843 D0 NO995843 D0 NO 995843D0 NO 995843 A NO995843 A NO 995843A NO 995843 A NO995843 A NO 995843A NO 995843 D0 NO995843 D0 NO 995843D0
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
vwf propeptide
vwf
propeptide
preparation
Prior art date
Application number
NO995843A
Other languages
English (en)
Other versions
NO324064B1 (no
NO995843L (no
Inventor
Hans-Peter Schwarz
Katalin Varadi
Peter Turecek
Hendrik Coenraad Hemker
Suzette Lucette Beguin
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Ag filed Critical Baxter Ag
Publication of NO995843D0 publication Critical patent/NO995843D0/no
Publication of NO995843L publication Critical patent/NO995843L/no
Publication of NO324064B1 publication Critical patent/NO324064B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19995843A 1997-05-28 1999-11-29 Farmasoytisk preparat omfattende vWF-propeptid samt fremgangsmate for fremstilling og anvendelse derav NO324064B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0091797A AT405485B (de) 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation
PCT/EP1998/003090 WO1998053848A1 (en) 1997-05-28 1998-05-26 PHARMACEUTICAL PREPARATION COMPRISING vWF PROPEPTIDE

Publications (3)

Publication Number Publication Date
NO995843D0 true NO995843D0 (no) 1999-11-29
NO995843L NO995843L (no) 2000-01-27
NO324064B1 NO324064B1 (no) 2007-08-06

Family

ID=3502803

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19995843A NO324064B1 (no) 1997-05-28 1999-11-29 Farmasoytisk preparat omfattende vWF-propeptid samt fremgangsmate for fremstilling og anvendelse derav

Country Status (10)

Country Link
US (2) US7005502B1 (no)
EP (1) EP0977584B1 (no)
JP (1) JP4335978B2 (no)
AT (2) AT405485B (no)
AU (1) AU744643B2 (no)
CA (1) CA2288737A1 (no)
DE (1) DE69802918T2 (no)
ES (1) ES2168766T3 (no)
NO (1) NO324064B1 (no)
WO (1) WO1998053848A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲viii▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
US7033994B2 (en) 1999-12-24 2006-04-25 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy
JP5022231B2 (ja) 2004-12-27 2012-09-12 バクスター・インターナショナル・インコーポレイテッド ポリマー−フォンビルブラント因子結合体
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
EP2010222A1 (en) 2006-03-31 2009-01-07 Baxter International Inc. Pegylated factor viii
JP5784907B2 (ja) * 2007-12-28 2015-09-24 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated 組換え型vwf製剤
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
ES2298096B1 (es) 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
TWI593421B (zh) 2008-10-21 2017-08-01 巴克斯歐塔公司 凍乾的重組vwf調配物
ES2713270T3 (es) * 2008-10-27 2019-05-20 Baxalta GmbH Modelos de ratón de púrpura trombocitopénica trombótica y métodos para su uso
SG178478A1 (en) 2009-08-20 2012-04-27 Baxter Int Purification of vwf for increased removal of non-lipid enveloped viruses
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
KR102104843B1 (ko) 2015-10-02 2020-04-28 에이에스엠엘 네델란즈 비.브이. 계측 방법 및 장치, 컴퓨터 프로그램 및 리소그래피 시스템
WO2019010496A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated TREATMENT OF PATIENTS WITH A SERIOUS FORM OF VON WILLEBRAND'S DISEASE UNRESENGING SURGICAL INTERVENTION BY RECOMBINANT VWF ADMINISTRATION
AU2018298233A1 (en) 2017-07-07 2020-01-30 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant VWF
EA202092223A1 (ru) 2018-03-21 2021-02-10 Баксалта Инкорпорейтед Разделение vwf и пропептида vwf хроматографическими методами
WO2020160460A1 (en) 2019-02-01 2020-08-06 Baxalta Incorporated Methods of prophylactic treatment using recombinant vwf (rvwf)
EP4028046B1 (en) 2019-09-11 2024-02-14 Takeda Pharmaceutical Company Limited Methods of treatment related to complexes of von willebrand factor and complement c1q
US20230398188A1 (en) 2020-02-04 2023-12-14 Takeda Pharmaceutical Company Limited Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT350726B (de) 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
AT378005B (de) 1983-08-20 1985-06-10 Linde Ag Verfahren zum desoxidieren von metallschmelzen
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
US5849536A (en) * 1990-03-02 1998-12-15 Bio-Technology General Corp. Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT398079B (de) 1991-11-04 1994-09-26 Immuno Ag Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung
EP0674531A1 (de) 1992-12-16 1995-10-04 IMMUNO Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
AT402788B (de) 1993-08-03 1997-08-25 Immuno Ag Virussichere blutgerinnungsfaktor xiii-präparation
JPH07330797A (ja) * 1994-05-31 1995-12-19 Sumitomo Metal Ind Ltd 新規細胞接着活性ペプチド
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
AT404359B (de) 1996-04-29 1998-11-25 Immuno Ag Gereinigte multimerase
AT404554B (de) 1996-04-29 1998-12-28 Immuno Ag Pharmazeutische präparation
US6068838A (en) 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase

Also Published As

Publication number Publication date
DE69802918T2 (de) 2003-04-10
DE69802918D1 (de) 2002-01-24
CA2288737A1 (en) 1998-12-03
ES2168766T3 (es) 2002-06-16
EP0977584A1 (en) 2000-02-09
EP0977584B1 (en) 2001-12-12
WO1998053848A1 (en) 1998-12-03
AU744643B2 (en) 2002-02-28
ATE210455T1 (de) 2001-12-15
NO324064B1 (no) 2007-08-06
US7005502B1 (en) 2006-02-28
AU7915698A (en) 1998-12-30
US7557188B2 (en) 2009-07-07
NO995843L (no) 2000-01-27
US20060003921A1 (en) 2006-01-05
AT405485B (de) 1999-08-25
JP4335978B2 (ja) 2009-09-30
ATA91797A (de) 1999-01-15
JP2001527579A (ja) 2001-12-25

Similar Documents

Publication Publication Date Title
NO995843D0 (no) Farmasöytisk preparat omfattende vWF-propeptid
ATE207349T1 (de) Thip zur behandlung von schlafstörungen
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
BR0113776A (pt) Composição de pirrolocarbazóis selecionados fundidos e método para tratar e prevenir várias doenças usando a citada composição
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
EA200100002A1 (ru) Бензотиепины, обладающие активностью ингибиторов перемещения желчных кислот в подвздошной кишке и поглощения таурхолата
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200000358A1 (ru) Способ получения диарилпиридинов, полезных в качестве ингибиторов cox-2
PT1305286E (pt) Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
FI963294A (fi) Naftyyliamidit keskushermostoaineina
PT865294E (pt) Processo para a reducao ou a manutencao de niveis reduzidos de lipidos no sangue utilizando composicoes de proteina ob
NO994822D0 (no) Immunotolerant protrombinkomplekspreparat
PT93959A (pt) Processo para a preparacao de derivados de sacarina uteis como inibidores proteoliticos de enzima
ATE239474T1 (de) Verwendung von levobupivacain
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
BR0012921A (pt) Compostos calcilìticos
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
DE69736180D1 (de) Behandlung von manischen erkrankungen
EA199800535A1 (ru) Способ лечения боли
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
NO995132L (no) Fremgangsmåte for reduksjon av fibrinogen
EA199800818A1 (ru) Способ лечения бессонницы

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAXALTA INCORPORATED, CH

MK1K Patent expired